Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence.
Depressive-like behavior is the most profound manifestation of autoimmunity-associated behavioral syndrome in lupus-prone MRL-lpr mice. This led to the hypothesis that chronic autoimmunity and inflammation alter the activity of central serotonergic and dopaminergic systems. Three drugs with a selective mode of action were used to probe the functional status of these two systems in vivo. The behavioral effects of single and repeated intraperitoneal (i.p.) injections of sertraline, quinpirole (QNP) and risperidone were measured in the forced swim and brief sucrose preference tests. In comparison to MRL +/+ controls, autoimmune MRL-lpr mice did not show a reduction in sucrose intake after the administration of sertraline. Acute injection of quinpirole increased floating more in the MRL-lpr than in the control group, while intermittent administration induced self-injurious behavior in both groups. Acute injection of risperidone significantly increased floating in MRL-lpr mice, while repeated administration abolished the difference between the substrains in sucrose intake. These discrepancies in responsiveness implied that the central neurotransmitter activity is dissimilar in the two MRL substrains. This notion was confirmed in a cohort of untreated MRL-lpr and MRL +/+ mice by comparing their neurotransmitter/metabolite levels in several brain regions. In particular, MRL-lpr brains showed increased dopamine (DA) levels in the paraventricular nucleus (PVN) and median eminence (ME), decreased concentrations of serotonin in the PVN and enhanced levels in the hippocampus, as well as decreased norepinephrine (NE) levels in the prefrontal cortex. Behavioral deficits correlated with the changes in PVN and median eminence. These results are consistent with the hypothesis that imbalanced neurotransmitter regulation of the hypothalamus-pituitary axis plays an important role in the etiology of behavioral dysfunction induced by systemic autoimmune disease.
Sakic
Boris
B
The Brain-Body Institute, McMaster University, Rm. H305, Father Sean O'Sullivan Research Center, St. Joseph's Healthcare, 50 Charlton Avenue East, L8N 4A6, Hamilton, Ontario, Canada. sakic@mcmaster.ca
Lacosta
Susan
S
Denburg
Judah A
JA
Szechtman
Henry
H
D000375:Aging / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000974:Antibodies, Antinuclear / Q000276:immunology / Q000378:metabolism; D001327:Autoimmune Diseases / Q000150:complications* / Q000235:genetics / Q000276:immunology; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D003863:Depression / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000235:genetics / Q000276:immunology; D008297:Male; D051379:Mice; D019463:Mice, Inbred MRL lpr; D009638:Norepinephrine / Q000378:metabolism; D019257:Quinpirole / Q000494:pharmacology; D018967:Risperidone / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D020280:Sertraline / Q000494:pharmacology; D013223:Statistics as Topic; D009435:Synaptic Transmission / Q000187:drug effects / Q000235:genetics / Q000276:immunology*
D000974:Antibodies, Antinuclear; D004298:Dopamine; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D009638:Norepinephrine; D019257:Quinpirole; D018967:Risperidone; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline